Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model

British Journal of Dermatology

Volumn 160, Issue 2, 2009, Pages 284-296

  Stenderup, K ^a   Rosada, C ^a   Worsaae, A ^b   Dagnaes Hansen, F ^c   Steiniche, T ^a   Hasselager, E ^b   Iversen, L F ^b   Zahn, S ^b   Woldike H ^b   Lindgreen Holmberg, H ^b   Romer J ^b   Kragballe, K ^a   Clausen, J T ^b   Dam, T N ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d ROSKILDE HOSPITAL   (Denmark)

Author keywords

Interleukin 20; Psoriasis; SCID mice

Indexed keywords

INTERLEUKIN 20;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LEUKOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; XENOGRAFT;

ADULT; AGED; ANIMALS; ANTIBODY SPECIFICITY; CELL PROLIFERATION; HUMANS; INTERLEUKINS; MICE; MICE, SCID; MIDDLE AGED; PSORIASIS; RECOMBINANT PROTEINS; REMISSION INDUCTION; SIGNAL TRANSDUCTION; SKIN TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 58349115638     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08890.x     Document Type: Article

References (44)

1. Blumberg H, Conklin D, Xu WF et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001 104 : 9 19.
2. Rømer J, Hasselager E, Norby PL et al. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine A or calcipotriol. J Invest Dermatol 2003 121 : 1306 11.
3. Wang F, Lee E, Lowes MA et al. Prominent production of IL-20 by CD68(+)/CD11c(+) myeloid-derived cells in psoriasis: gene regulation and cellular effects. J Invest Dermatol 2006 126 : 1590 9.
4. Wei CC, Chen WY, Wang YC et al. Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol 2005 117 : 65 72.
5. Otkjaer K, Kragballe K, Funding AT et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol 2005 153 : 911 18.
6. Dumoutier L, Leemans C, Lejeune D et al. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001 167 : 3545 9.
7. Pletnev S, Magracheva E, Kozlov S et al. Characterization of the recombinant extracellular domains of human interleukin-20 receptors and their complexes with interleukin-19 and interleukin-20. Biochemistry 2003 42 : 12617 24.
8. Rich BE, Kupper TS. Cytokines: IL-20 - a new effector in skin inflammation. Curr Biol 2001 11 : R531 4.
9. Parrish-Novak J, Xu W, Brender T et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002 277 : 47517 23.
10. Sano S, Chan KS, Carbajal S et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005 11 : 43 9.
11. Hsieh MY, Chen WY, Jiang MJ et al. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun 2006 7 : 234 42.
12. Tritsaris K, Myren M, Ditlev SB et al. IL-20 is an arteriogenic cytokine that remodels collateral networks and improves functions of ischemic hind limbs. Proc Natl Acad Sci U S A 2007 104 : 15364 9.
13. Kingo K, Koks S, Nikopensius T et al. Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun 2004 5 : 117 21.
14. Koks S, Kingo K, Ratsep R et al. Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis. Genes Immun 2004 5 : 662 7.
15. Koks S, Kingo K, Vabrit K et al. Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun 2005 6 : 407 15.
16. Boehncke WH, Sterry W, Hainzl A et al. Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice. Arch Dermatol Res 1994 286 : 325 30.
17. Dam TN, Kang S, Nickoloff BJ et al. 1alpha, 25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 1999 113 : 1082 9.
18. Nickoloff BJ, Kunkel SL, Burdick M et al. Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 1995 146 : 580 8.
19. Boehncke WH, Kock M, Hardt-Weinelt K et al. The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs. Arch Dermatol Res 1999 291 : 104 6.
20. Villadsen LS, Schuurman J, Beurskens F et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003 112 : 1571 80.
21. Villadsen LS, Skov L, Dam TN et al. In situ depletion of CD4(+) T cells in human skin by zanolimumab. Arch Dermatol Res 2007 298 : 449 55.
22. Kunz S, Wolk K, Witte E et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006 15 : 991 1004.
23. Chan JR, Blumenschein W, Murphy E et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006 203 : 2577 87.
24. Raychaudhuri SP, Sanyal M, Weltman H et al. K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol 2004 122 : 812 19.
25. Schon MP, Krahn T, Schon M et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 2002 8 : 366 72.
26. Zeigler M, Chi Y, Tumas DB et al. Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with cyclosporin A and clobetasol propionate. Lab Invest 2001 81 : 1253 61.
27. Zollner TM, Podda M, Pien C et al. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 2002 109 : 671 9.
28. Sa SM, Valdez PA, Wu J et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007 178 : 2229 40.
29. Wolk K, Kunz S, Asadullah K et al. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002 168 : 5397 402.
30. Liu L, Ding C, Zeng W et al. Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20. Blood 2003 102 : 3206 9.
31. Curry JL, Qin JZ, Robinson J et al. Reactivity of resident immunocytes in normal and prepsoriatic skin using an ex vivo skin-explant model system. Arch Pathol Lab Med 2003 127 : 289 96.
32. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999 155 : 145 58.
33. Skov L, Kragballe K, Zachariae C et al. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol 2003 139 : 1433 9.
34. Lowes MA, Chamian F, Abello MV et al. Increase in TNF-{alpha} and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005 102 : 19057 62.
35. Boyman O, Hefti HP, Conrad C et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004 199 : 731 6.
36. Chen WY, Cheng BC, Jiang MJ et al. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006 26 : 2090 5.
37. Gilhar A, Ullmann Y, Kerner H et al. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 2002 119 : 384 91.
38. Boniface K, Lecron JC, Bernard FX et al. Keratinocytes as targets for interleukin-10-related cytokines: a putative role in the pathogenesis of psoriasis. Eur Cytokine Netw 2005 16 : 309 19.
39. Heuze-Vourc'h N, Liu M, Dalwadi H et al. IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem Biophys Res Commun 2005 333 : 470 5.
40. Hosoi T, Wada S, Suzuki S et al. Bacterial endotoxin induces IL-20 expression in the glial cells. Brain Res Mol Brain Res 2004 130 : 23 9.
41. Kragballe K. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark. Br J Dermatol 2007 156 (Suppl. 2 7 11.
42. Lebwohl M. Psoriasis. Lancet 2003 361 : 1197 204.
43. Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003 3 : 148 55.
44. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 345 : 1098 104.